Vascular Dysfunction in Horses with Endocrinopathic Laminitis.
Endocrinopathic laminitis (EL) is a vascular condition of the equine hoof resulting in severe lameness with both welfare and economic implications. EL occurs in association with equine metabolic syndrome and equine Cushing's disease. Vascular dysfunction, most commonly due to endothelial dysfunction, is associated with cardiovascular risk in people with metabolic syndrome and Cushing's syndrome. We tested the hypothesis that horses with EL have vascular, specifically endothelial, dysfunction. Healthy horses (n = 6) and horses with EL (n = 6) destined for euthanasia were recruited. We studied vessels from the hooves (laminar artery, laminar vein) and the facial skin (facial skin arteries) by small vessel wire myography. The response to vasoconstrictors phenylephrine (10-9-10-5M) and 5-hydroxytryptamine (5HT; 10-9-10-5M) and the vasodilator acetylcholine (10-9-10-5M) was determined. In comparison with healthy controls, acetylcholine-induced relaxation was dramatically reduced in all intact vessels from horses with EL (% relaxation of healthy laminar arteries 323.5 ± 94.1% v EL 90.8 ± 4.4%, P = 0.01, laminar veins 129.4 ± 14.8% v EL 71.2 ± 4.1%, P = 0.005 and facial skin arteries 182.0 ± 40.7% v EL 91.4 ± 4.5%, P = 0.01). In addition, contractile responses to phenylephrine and 5HT were increased in intact laminar veins from horses with EL compared with healthy horses; these differences were endothelium-independent. Sensitivity to phenylephrine was reduced in intact laminar arteries (P = 0.006) and veins (P = 0.009) from horses with EL. Horses with EL exhibit significant vascular dysfunction in laminar vessels and in facial skin arteries. The systemic nature of the abnormalities suggest this dysfunction is associated with the underlying endocrinopathy and not local changes to the hoof.
University/BHF Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom.|Royal (Dick) School of Veterinary Studies, University of Edinburgh, Midlothian, United Kingdom.
Ruth A
RA
Morgan
Royal (Dick) School of Veterinary Studies, University of Edinburgh, Midlothian, United Kingdom.
John A
JA
Keen
University/BHF Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom.
Brian R
BR
Walker
University/BHF Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom.
Patrick W F
PW
Hadoke
Equine Vet J. 2004 Apr;36(3):295-8
15147141
J Vet Pharmacol Ther. 2013 Aug;36(4):382-8
22943152
Am J Vet Res. 2010 Mar;71(3):281-7
20187829
Am J Vet Res. 1995 Oct;56(10):1338-44
8928952
Equine Vet J. 2011 Nov;43(6):744-9
21496102
Domest Anim Endocrinol. 2011 Oct;41(3):111-7
21696910
Curr Vasc Pharmacol. 2014;12(6):829-35
24066936
Hypertension. 1996 Feb;27(2):190-6
8567040
Vet Clin North Am Equine Pract. 2010 Apr;26(1):135-40
20381742
Am J Hypertens. 2000 Nov;13(11):1155-60
11078174
Cardiovasc Res. 2009 Jun 1;82(3):493-502
19289377
Vet J. 2011 Sep;189(3):248-56
21665498
J Clin Invest. 1996 Jun 1;97(11):2601-10
8647954
Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13357-62
10557325
Endocrine. 2007 Jun;31(3):300-4
17906379
J Vasc Res. 1998 Jan-Feb;35(1):18-26
9482692
J Am Coll Cardiol. 2001 May;37(6):1523-8
11345360
Hypertension. 1996 Jun;27(6):1245-53
8641731
Am J Vet Res. 1999 Feb;60(2):233-9
10048558
J Appl Physiol (1985). 1988 Apr;64(4):1580-3
3378993
Crit Care Med. 2011 Apr;39(4):878-9
21613831
Am J Cardiol. 2004 Apr 15;93(8):1012-6
15081445
Equine Vet J. 2004 Apr;36(3):194-8
15147123
Equine Vet J. 1998 Mar;30(2):124-30
9535068
Circulation. 2002 Feb 19;105(7):804-9
11854119
Equine Vet J. 2004 Jan;36(1):41-5
14756370
Cell Tissue Res. 2009 Jan;335(1):191-203
18797930
J Clin Endocrinol Metab. 2012 May;97(5):1702-11
22419708
Vet Clin North Am Equine Pract. 2010 Apr;26(1):141-53
20381743
J Vasc Surg. 2003 Nov;38(5):1067-74
14603219
Vet Immunol Immunopathol. 2009 Feb 15;127(3-4):286-94
19097648
Curr Hypertens Rep. 2015 Nov;17(11):85
26371063
Am J Vet Res. 1985 Jul;46(7):1545-9
4026037
Equine Vet J. 2002 Nov;34(7):679-85
12455838
Equine Vet J. 2016 Jul;48(4):472-8
25869529
Lancet. 1983 Apr 23;1(8330):904-6
6132223
Am J Vet Res. 2007 Jul;68(7):722-9
17605607
Eur J Cardiovasc Prev Rehabil. 2011 Dec;18(6):775-89
21450600
Br J Pharmacol. 2009 Mar;156(5):689-712
19239478
J Clin Endocrinol Metab. 2003 Jun;88(6):2527-33
12788849
J Intern Med. 2000 Feb;247(2):198-204
10692082
Equine Vet J. 1988 Jan;20(1):41-5
3366105
Equine Vet J. 1999 May;31(3):212-8
10402134
Aust Vet J. 2014 Apr;92(4):101-6
24673135
Circulation. 2002 Feb 5;105(5):576-82
11827922
Biochem Biophys Res Commun. 1997 Nov 17;240(2):298-303
9388472
Int J Obes Relat Metab Disord. 1999 Sep;23 (9):936-42
10490799
J Vet Intern Med. 2010 Jul-Aug;24(4):932-9
20649750
Circ Res. 1976 Aug;39(2):245-54
939010
Equine Vet J. 2009 Feb;41(2):171-8
19418747
J Pharmacol Toxicol Methods. 2008 Mar-Apr;57(2):92-9
18280185
Am J Physiol. 1999 Jul;277(1 Pt 2):R190-7
10409273
Atherosclerosis. 2003 Dec;171(2):303-9
14644401
Nutr Metab Cardiovasc Dis. 2011 Oct;21(10):808-16
20554176
Circ Res. 2003 Jan 10;92(1):81-7
12522124
Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):1022-9
25657309
J Appl Physiol (1985). 2006 Mar;100(3):759-63
16269525
Vet J. 2013 Oct;198(1):57-69
24070987
Clin Exp Pharmacol Physiol. 1988 Apr;15(4):305-10
3271611
J Cardiovasc Pharmacol. 1996 Jul;28(1):60-7
8797137
Vet J. 2007 Nov;174(3):530-5
17719811
Clin Endocrinol (Oxf). 2007 Apr;66(4):586-92
17371479
J Clin Invest. 2000 Feb;105(3):311-20
10675357
J Am Vet Med Assoc. 1975 Jan 1;166(1):58-62
1110201
Equine Vet J. 2005 Nov;37(6):546-51
16295933
J Vet Pharmacol Ther. 2006 Oct;29(5):387-95
16958783
Vet J. 2014 Oct;202(1):83-8
25155219
Ann Intern Med. 2004 Nov 16;141(10):764-70
15545676
Am J Vet Res. 2008 Jan;69(1):122-9
18167097